Alendronate Sodium Articles
Another Fosamax trial success for Merck & Co
4 October 2011
Two US FDA advisory panels say osteoporosis drugs need label changes
12 September 2011
Merck & Co wins first Fosamax state court trial; new study finds low osteonecrosis risk for bisphosphonates
15 February 2011
Jury rejects plaintiff’s claim against Merck & Co in another federal Fosamax bellwether trial
22 November 2010
USA’s FDA calls for label changes on bisphosphonates due to possible increased risk of thigh bone fracture
14 October 2010
Bisphosphonates under scrutiny in Europe over link to stress fractures
28 September 2010
Drug's effect on reduction of new hip fractures is greatest influence on Rxing decisions, says DR report
5 March 2010
One cheer for Pfizer’s Fablyn
26 February 2010
First federal trial of Merck & Co’s Fosamax declared a “mistrial”
14 September 2009
Generic drugs "saved USA $734B" since 1999, GPhA says, more than cost of TARP bank bail out
11 May 2009
Merck & Co 1st-qtr profit slumps 57%
21 April 2009
Ipsen's revenues up 6% on new US launches
9 February 2009
US generic sales value falls, despite volume rise
19 January 2009
Merck & Co's 2009 outlook below predictions due to forex effects and restructuring costs
15 December 2008
FDA finds no AF link for bisphosphonates
24 November 2008
NHS physicians "under pressure" to switch Rxs
6 October 2008
Merck & Co income still up despite low sales
28 July 2008
Denosumab increases BMD in ADT patients
21 July 2008
NOS slams NICE rules on 2nd-line osteo drugs
14 July 2008
Denosumab's BMD gain greater than Fosamax
9 June 2008
Amgen
26 May 2008
Wal-Mart price war aimed at PBMs
19 May 2008
Wal-Mart expands drug program to 90 days
12 May 2008
Watson's 1st-qtr 2008 net income jumps 60%
12 May 2008
Ipsen reports 8.4% sales growth in 1st qtr
12 May 2008
Merck & Co shares fall 5.1% after
5 May 2008
Teva says Dutch part of MSD's Fosamax patent revoked
3 March 2008
UPDATE: GPhA sees US prospects in 2008, Rx share at 65%
25 February 2008
Stock Commentary - New York week to Feb 18, 2008
25 February 2008
Generic Rxing hits 65% of US market
25 February 2008
Watson and Barr launch generic Fosamax in USA
11 February 2008
Vioxx costs see Merck & Co swing to $1.6B loss
4 February 2008
FDA warns: severe pain with bisphosphonates
14 January 2008
Patent expiry for 2008 provides generic opportunity
14 January 2008
US Rx drug market in relative decline
12 November 2007
Merck & Co's 3rd-qtr 2007 sales jump 12%
29 October 2007
Merck & Co's 2nd-qtr 2007 EPS jumps 12%
30 July 2007
Merck & Co's 1st-qtr income climbs 12%
30 April 2007
Merck & Co's 4th-qtr income plunges 58%
5 February 2007
Ipsen licenses MSD's Adrovance in France
5 February 2007
Positive results for Merrion's osteoporosis drug
22 January 2007
Canada: new formulary for new year - Ontario introducing reform
15 January 2007
13 new drugs added to Japan's NHI list
18 September 2006
Merck & Co sees 1st-qtr net income of $1.52B
1 May 2006
Trial subjects favor once-daily Bonviva
27 March 2006
Merck & Co beats forecasts; profit up 2%
6 February 2006
USA
22 August 2005
Complex result in Forteo vs Fosamax trial
15 August 2005
Tax charges slice Merck & Co's 2nd-qtr income
1 August 2005
Stock Commentary - New York
30 May 2005
Hungary: same subsidy for all drugs in a group
25 April 2005
Hungary: same subsidy for all drugs in a group
25 April 2005
Vioxx loss drags on Merck & Co results
22 April 2005
FDA clears Merck & Co's enhanced Fosamax
18 April 2005
Merck & Co's first taste of life after Vioxx; earnings per share to take substantial hit
20 December 2004
Promising new data for Amgen's AMG-162
11 October 2004
Merck & Co 2nd-qtr profit dips 2%
26 July 2004
Merck & Co reports 5% drop in 1st-qtr income
3 May 2004
Fosamax compares well against rivals
19 April 2004
Significant BMD rise seen with Fosamax
29 March 2004
Merck & Co 4th-qtr in line with estimates; net income down 23%
2 February 2004
US DTC ad spend, and response, levels off
20 October 2003
...while Lilly says Forteo has significant benefits over Fosamax
29 September 2003
HRT sales to plummet, osteoporosis market to benefit?
22 September 2003
Teva set to contest Fosamax court ruling
8 September 2003
Roche's Bonviva cleared by US FDA
26 May 2003
NPS drug for osteoporosis on track in Ph II/III
10 March 2003
Once-weekly Actonel launched in UK
10 February 2003
Stock Commentary - Week to January 27 - New York
3 February 2003
Merck & Co to appeal UK Fosamax patent ruling
27 January 2003
Teva gets tentative FDA go-ahead for generic Fosamax
6 January 2003
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
